Oyster Point Pharma, Inc.
OYSTDelisted Jan 3, 2023- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001720725
Oyster Point Pharma, Inc. was delisted on Jan 3, 2023; its insiders filed their last Form 4 on Jan 5, 2023; 53 institutions reported holding it in 13F filings for Q4 2022, worth $189.4M in total; no superinvestor held it.
Q2 2021 vs. Q1 2021
How the institutions holding Oyster Point Pharma, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 61 | 58 | −3 |
| Shares | 18.4M | 18.5M | +142.5K (+0.8%) |
| Value | $335.9M | $318.3M | −$17.6M (−5.2%) |
New holders (8)
Institutions that held Oyster Point Pharma, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| ACT Capital Management, LLC | 31,500 | $542.0K | 0.28% |
| Gsa Capital Partners LLP | 25,569 | $440.0K | 0.05% |
| Rhumbline Advisers | 10,651 | $183.0K | 0.00% |
| Susquehanna International Group, LLP | 10,448 | $180.0K | 0.00% |
| Evoke Wealth, LLC | 320 | $6.00K | 0.00% |
| Panagora Asset Management Inc | 296 | $5.00K | 0.00% |
| Manchester Capital Management LLC | 22 | $0 | 0.00% |
| State of Wyoming | 6 | $0 | 0.00% |
Sold out (11)
Institutions that held Oyster Point Pharma, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Lexington Partners L.P. | 27,408 | $501.0K |
| Alyeska Investment Group, L.P. | 21,898 | $400.0K |
| Adams Street Partners LLC | 21,625 | $395.0K |
| Jacobs Levy Equity Management, Inc | 19,830 | $362.0K |
| Virtus ETF Advisers LLC | 14,995 | $274.0K |
| ExodusPoint Capital Management, LP | 13,377 | $245.0K |
| Hamilton Lane Advisors LLC | 11,521 | $211.0K |
| California Public Employees Retirement System | 10,700 | $196.0K |
| HighTower Advisors, LLC | 10,240 | $187.0K |
| StepStone Group LP | 4,461 | $82.0K |
| Bank of Montreal | 186 | $4.00K |